第一东方心经马报资料网主办
»您现在的位置: 第一东方心经马报资料网 >> 财经东方心经马报资料 >> 文传商讯 >> 正文

New data reinforces benefits of Spiolto Respimat in improving patient outcomes

2019/10/8 14:40:23  文章来源:文传商讯  作者:文传商讯
文章简介: DatasupportstheefficacyandsafetyprofileofSpioltoRespimat1 Resultsfromonestudyemphasisepatientsatisfactionandease-of-usewithRespimatinhal

Data supports the efficacy and safety profile of Spiolto Respimat1
Results from one study emphasise patient satisfaction and ease-of-use with Respimat inhaler 2
Two formative usability studies underscore the patient-centric design and enhanced usability of Respimat re-usable inhaler3

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim announced Spiolto® (tiotropium/olodaterol) Respimat® data being presented at the European Respiratory Society (ERS) 2019 Congress. The results show the benefits of tiotropium/olodaterol in improving symptoms and lung function as well as patients’ satisfaction when inhaling from and handling the tiotropium/olodaterol soft-mist inhaler.1,2,3,4 The results of these studies reinforce the importance of patient needs and preferences as well as patients’ ability to properly inhale when prescribing inhaler therapy for COPD management.

“The importance of matching a specific inhaled therapy with patients’ personal needs and preferences cannot be overstated in COPD management,” said Prof Paola Rogliani, Head of Clinical Respiratory Unit, Policlinico Tor Vergata, Rome, Italy. “A novel bidimensional, pooled analysis enabled us to directly compare six LAMA/LABA fixed-dose combinations and demonstrate that tiotropium/olodaterol improved patient outcomes more than the other treatments in the class. Varying efficacy and safety of combinations in the same class should be considered for a patient-centred approach in COPD.”

Data presented at ERS reinforces the benefits of tiotropium/olodaterol LAMA/LABA* therapy in improving patient outcomes, specifically:1,4

- A pooled analysis exploring the effect of step-up COPD treatment from tiotropium at baseline to tiotropium/olodaterol,4 showed that optimising bronchodilation with tiotropium/olodaterol led to clinically relevant improvements in lung function, health status and breathlessness.4
- A bidimensional comparative analysis looked at the efficacy and safety profile of six LAMA/LABA fixed-dose combinations and found tiotropium/olodaterol surpassed all others in-class in terms of efficacy, while also having fewer cardiovascular serious adverse events.1

Further data presented reinforce satisfaction, inhaleability and ease of use associated with the tiotropium/olodaterol inhaler:2,3

- An open-label, observational study evaluating patients’ general condition as well as treatment and device satisfaction in COPD patients treated with tiotropium/olodaterol, found improved general condition as well as high satisfaction with handling and inhaling from the tiotropium/olodaterol device as reported by patients.2
- To guide the development of an enhanced tiotropium/olodaterol inhaler, two formative studies evaluating COPD patients’ general handling of the tiotropium/olodaterol and the tiotropium/olodaterol re-usable inhalers confirmed that a patient-centric design led to an enhanced tiotropium/olodaterol re-usable inhaler with improved usability and easier-to-read dose indicator.3

These findings are significant because in addition to the importance of individualising treatment, the internationally-recognised GOLD‡ guidance document emphasises considering patient preferences and ability to use their inhaler when prescribing a specific COPD therapy.5 Studies suggest that up to 52% of COPD patients struggle to inhale from their device (including those with mild disease),6,7 and the ability to properly inhale medication plays a key role in COPD management.8,9

“As a company, we have been developing therapies and inhaler devices for people with respiratory conditions for almost a century,” said Dr Alberto de la Hoz, Global Head of Medical Affairs, Respiratory Franchise at Boehringer Ingelheim. “The data presented at ERS underscore the efficacy of tiotropium/olodaterol as a treatment for COPD patients with different clinical characteristics and needs, and how the Respimat® re-usable was enhanced based on HCP and patient feedback, addressing their evolving needs and preferences.”

Boehringer Ingelheim will present data from 11 abstracts relating to the COPD portfolio, host two scientific symposia and post daily podcasts featuring leading respiratory experts throughout the ERS Congress. To find out more, visit the Boehringer Ingelheim ERS webpage: https://congresscoverage.com/BI/congress/ers2019

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

For references and notes to editors, please visit: http://www.boehringer-ingelheim.com/press-release/spiolto-respimat-improves-patient-outcomes-copd

* Long-acting muscarinic antagonists/long-acting beta2 agonists
‡ Global Initiative for Chronic Obstructive Lung Disease (GOLD) Strategy for the Diagnosis, Management, and Prevention of COPD

分享到:
第一东方心经马报资料网免责声明:
1、本网站中的文章(包括转贴文章)的版权仅归原作者所有,若作者有版权声明的或文章从其它网站转载而附带有原所有站的版权声明者,其版权归属以附带声明为准。
2、文章来源为均为其它媒体的转载文章,我们会尽可能注明出处,但不排除来源不明的情况。转载是处于提供更多信息以参考使用或学习、交流、科研之目的,不用于 商业用途。转载无意侵犯版权,如转载文章涉及您的权益等问题,请作者速来电话和函告知,我们将尽快处理。来信:fengyueyoubian#sina.com (请将#改为@)。
3、本网站所载文章、数据、网友投稿等内容纯属作者个人观点,仅供投资者参考,并不构成投资建议,与第一东方心经马报资料网站无关。投资者据此操作,风险自担。如对本文内容有疑义,请及时与我们联系。
发表评论

【发表评论】(网友评论内容只代表网友观点,与本站立场无关!)
 姓 名:
 评 分: 1分 2分 3分 4分 5分
 评论内容:
验证码:   *
  • 请遵守《互联网电子公告服务管理规定》及中华人民共和国其他各项有关法律法规。
  • 严禁发表危害国家安全、损害国家利益、破坏民族团结、破坏国家宗教政策、破坏社会稳定、侮辱、诽谤、教唆、淫秽等内容的评论 。
  • 用户需对自己在使用本站服务过程中的行为承担法律责任(直接或间接导致的)。
  • 本站管理员有权保留或删除评论内容。
  • 评论内容只代表网友个人观点,与本网站立场无关。
  • 全站精选
    [新闻]  我和我的祖国70周年国庆节手抄报内容资料素材大
     国庆节主题手抄报模板大全:建国70周年国庆节手
    [银行]  2019银行概念股票一览?财政部新规引发银行股飘
     2019银行从业资格证报名时间 报名需要什么条件?
    [股票]  我国又发现10亿吨级大油田 中国石油市值大增超2
     十亿吨级大油田被发现 四川盆地超万亿方页岩气区
    [基金]  200余家上市公司获真金白银增持 有你的票吗?
     基民"嗨了"!这20只基金狂赚70%以上,前三季度冠
    [保险]  人保车险理赔时间规定
     职工医保和新农合医保哪个好?主要看这三点
    [期货]  国庆节后国内油价或迎“三连涨”
     原油暴涨暴跌波及化工产业 去年苯乙烯价差超600
    [股评]  下周二最具爆发力六大黑马(10/8)
     六大券商下周二看好六大板块(10/8)
    [港股]  港股通中秋休市安排2019:开市时间9月16日起
     阿里20亿美元全资收购网易考拉并领投网易云音乐
    [美股]  百度卖携程股份,价值十亿美元
     WeWorkceo离职怎么回事?还拟裁员5000!WeWork还
    [外汇]  华尔街突遭“美元荒” 本周重点关注欧美制造业P
     17日人民币对美元汇率中间价下调73个基点
    [债券]  2019国庆假期国债逆回购时间表 让你小长假躺着赚
     中国10年国债收益率 今年波幅七年来最小
    [黄金]  2020庚子鼠年贺岁银条哪里预约?怎么购买?
     中国为何不把存美国黄金运回?因为美国不敢私吞
    [东方心经马报]  微信支付宝绑定银行卡的 赶紧删了手机里这些照片
     组图:网友前置摄像头跟拍那英 疑似惹对方不满遭
    [信托]  跌破8% 集合信托收益或继续下跌
     信托违约增多 预期收益9%的产品还能买吗?
    [东方心经彩图]  楼市调控坚持“房住不炒” “金九银十”或成色不
     陕西秦岭保护再升级:违建最高罚两百万
    [东方心经马报资料]  4年亏损220亿,蔚来迎战艰难时刻
     10月25日上市! 丰田全新RAV4配多种动力系统
  • 此栏目下没有推荐文章
  • | 设为首页 | 加入收藏 | 关于我们 | 友情链接 | 版权申明 | 文章列表 | 网站地图 | 征稿启事 | 广告服务 | 意见反馈 |

    Copyright©2006-2027 afinance.cn All Rights Reserved 版权所有·第一东方心经马报资料网 ,未经授权禁止复制或建立镜像,否则将依法追究法律责任!

    声明:我们不做任何形式的代客东方心经马报及投资指导,凡是以第一东方心经马报资料网名义做股票推荐的行为均属违法!

    广告商的言论与行为均与第一东方心经马报资料网无关!股市有风险,投资需谨慎。

    合作邮箱:fengyueyoubian@sina.com 合作电话:18678839953 点击这里给我发消息